Assessing the Risk and Potential of BridgeBio Pharma Inc’s (BBIO) Stock
The stock of BridgeBio Pharma Inc (BBIO) has seen a 6.97% increase in the past week, with a 29.69% gain in the past month, and
The stock of BridgeBio Pharma Inc (BBIO) has seen a 6.97% increase in the past week, with a 29.69% gain in the past month, and
The stock of BridgeBio Pharma Inc (BBIO) has seen a 19.95% increase in the past week, with a 16.15% gain in the past month, and
BBIO has 36-month beta value of 1.05. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 6 as “overweight,”
The stock of BridgeBio Pharma Inc (BBIO) has gone down by -1.16% for the week, with a 6.02% rise in the past month and a
Company’s 36-month beta value is 1.06.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 7 as “overweight,” 2 as
The stock of BridgeBio Pharma Inc (BBIO) has gone down by -10.35% for the week, with a 16.24% rise in the past month and a
BridgeBio Pharma (NASDAQ:BBIO) and Maze Therapeutics recently announced the formation of a partnership, Contour Therapeutics, to transform and advance innovative approaches to precision medicine for
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.